Daraxonrasib, a drug that targets the genetic driver of most pancreatic cancers, extended clinical trial participants’ progression-free survival by a median of 8.5 months, according to a study published May 6 in The New England Journal of Medicine.
Fifteen cancer centers participated in the research: Boston-based Dana-Farber Cancer Institute; New York City-based Memorial Sloan Kettering Cancer Center; Salt Lake City-based Huntsman Cancer Institute; New York City-based NYU Langone Health; Cincinnati-based Christ Hospital; Dallas-based Mary Crowley Cancer Research; Nashville-based Sarah Cannon Research Institute; New York City-based Columbia University; Baltimore-based Johns Hopkins Sidney Kimmel Comprehensive Cancer Center; David Geffen School of Medicine at the University of California Los Angeles; University of California Irvine; Miami Cancer Institute; Houston-based University of Texas MD Anderson Cancer Center; Fairfax-based NEXT Oncology Virginia-Virginia Cancer Specialists Research Institute; and San Antonio, Texas-based NEXT Oncology.
Here are five things to know from the study:
- Trial participants had stage 4 pancreatic cancer and previously received one line of chemotherapy that was no longer working. Of the 168 patients enrolled in the trial, 35% responded to the drug.
- While the median progression-free survival time was 8.5 months, the median overall survival was 13.1 months.
- One in three patients experienced significant side effects, such as rash, nausea, diarrhea and mouth sores, but no patient discontinued treatment due to side effects.
- The FDA granted expanded access to daraxonrasib, which is developed by Revolution Medicines, through a “safe to proceed” letter issued May 1.
- A phase 3 trial of daraxonrasib is underway at more than 30 cancer centers in the U.S.
Read the full study here.
At the Becker's Perioperative Summit, taking place September 14–15 in Chicago, perioperative leaders and healthcare executives will focus on improving operating room efficiency, enhancing patient safety, optimizing staffing and driving innovation across surgical services. Apply for complimentary registration now.
